Abstract: The first International Symposium on Animal Genomics for Animal Health (AGAH) provided an excellent venue for scientists working in the field of genomics to interact with animal health experts. This paper provides an introduction to genome-enabled tools and highlights some of the research projects in the AGAH proceedings. A brief review of animal genomes, the next generation of genetic markers, and the versatility of genome-enabled technologies and their many applications are discussed.
INTRODUCTION
Animal genomics is a new field of research defined by rapidly evolving genomeenabled technologies derived from the recent breakthroughs in sequencing whole animal genomes. Although the field originated decades ago with the identification of genetic markers that led to the assembly of genetic and physical maps, the promise of animal genomics was not realized until the sequencing and annotation of the human genome was achieved in 2002. Since then, the explosion of new highthroughput technologies arising from the genomics field has been enabling the analysis of entire animal genomes, transcriptomes, and proteomes, providing links between the genetic code and the diversity of living organisms. Importantly, genomeenabled technologies are providing new opportunities for understanding disease mechanisms and novel approaches for improving the health and welfare of animals.
GENOME-ENABLED RESEARCH TOOLS

Animal genomes
After 13 years of hard work and dedication, a major milestone in biomedical research was reached in 2003, by a consortium of international scientific institutions, with the completion of the human genome project [1] . The goal of the project was to identify the estimated 25,000 genes in human DNA, determine the three billion nucleic acid base pairs that make up human DNA, store this information in databases, develop and improve tools for data analysis, transfer related technologies to the private sector, and address ethical and social issues that may arise from these technologies. The human genome project has since generated ground-breaking research tools such as the haplotype map of the human genome, consisting of the genome-wide detection and characterization of single nucleotide polymorphisms (SNP5) [2, 3] . These genome-enabled technologies have clearly catalyzed the multibillion-dollar biotechnology industry [4] and are fostering the development of powerful tools in biomedical research [5] [6] [7] . However, these initial accomplishments have highlighted the need for the sequence of multiple animal species and the need for comparisons to fully explore the unknown world of genomic information [8] .
The animal health research community is now in a position to capitalise on the infrastructure built by the human genome project with the sequencing of important animal species [9] : the chicken (Gal/us gal/us) in 2004 [10, 11] ; the dog (Canis lupus familiaris) in 2004 [12, 13] ; the cow (Bos taurus) in 2004 [14] ; the cat (Fe/is catus) in 2006 [15] ; and sequencing initiated for the pig (Sus scrofa) [16] and horse (Equus cabal/us) [17] genomes. Together, these projects provide the foundation for the field of animal genomics. A critical area will be the sequencing of genomes within animal species that demonstrate differences in disease susceptibility. Initial results of whole genome comparisons are already predicting that the field of comparative genomics will yield rich returns in biomedical research [8] . Successful examples are already given by the development of animal models to address human diseases and new tools to create comparative phenotypic models [18] . Likewise, the animal health research community now has access to powerful research tools to discover effective measures to prevent, diagnose, and treat diseases.
Bioinformatics and computational biology
The sequencing of animal genomes has generated an unprecedented amount of information, starting with the identification of billions of nucleotide base pairs, the identification of regulatory sequences that control gene expression, genetic markers, regulatory sequences in non-coding RNA, the transcriptome and proteome, and the three-dimensional structure of native molecules. Transforming this information into practical understanding requires intensive data-mining using sophisticated computational and bioinformatics tools. Highly intensive computations using supercomputers have greatly facilitated this process. Still needed are the development of public databases of the completely annotated genomic sequence data sets of many hosts, sequencebased high-throughput expression profiling technologies, and integrated bioinformatics tools to analyze and interpret genomic data. Integrating genetic, functional genomic, and bioinformatics data in a systems biology approach to complex diseases is developing in a promising way.
PINARD-VAN DER LAANIGAY
A new generation of genetic markers
Genetic markers can be simply defined as variations that are genetically controlled and inherited in a Mendelian way. Historically, there has been a continuous evolution of DNA markers developed and used thanks to technological progress, from the generation of restriction fragment length polymorphisms (RFLPs) and variable number tandem repeats (VNTRs) to PCR techniques that enable the development ofmicrosatellite markers, all of which have been extensively used for genetic studies like quantitative trait loci (QTL) detection of disease resistance traits (see examples in these proceedings).
Another important area has been the discovery of "candidate genes," which represent a special group of genetic markers that can be used as markers of closely linked genes or studied as direct candidate genes. In disease resistance association studies, and immunogenetics studies in livestock, Major Histocompatibility Complex (MHC) genes have historically been the candidate genes of choice and several examples are presented in these proceedings. But with advanced genomics tools like pyrosequencing-based SNP typing, the identification of novel polymorphisms will progress rapidly.
With the availability of animal genome sequences, a new era of genome-enabled technologies is foretelling the feasibility of rapidly identifying genetic markers using emerging high-throughput novel technologies. Good examples are high density SNP panels. This new generation of genetic markers is paving the way for conducting fully automated whole genome scans to quickly genotype a large number of animals for a significant number of SNPs. These genetic markers are now the tools of choice to further dissect complex traits like disease resistance. High throughput technologies using dense DNA chips to type tens of thousands of SNPs are also becoming routinely available. The impact of this research will not be achieved until the "annotation" of the animal genomes is completed, which will require identifying all the genes, their location and function. Large international annotation initiatives are needed to identify functional elements within the genome sequences that can potentially lead to the identification of SNPs responsible for the observed variations in disease resistance.
The discovery of other markers is likely to present as yet unexplored sources of genetic variation. For example, copy number variations (CNV5) are genomic structural variations observed within and between breeds that may have a possible effect on health traits [19] . Although, at the beginning ofthis paper, we defined genetic markers as being inherited in a Mendelian pattern, another area to consider will be the growing evidence that a significant part of the genetic variation in observed phenotypes may be due to polymorphisms in imprinted genes [20] .
Genetic markers are essentially tools with two purposes: the first is identifying and mapping QTL/genes of traits of interest and the second is application in breeding (see below). Protocols to identify QTL of disease resistance in livestock species are often complex and costly and may be hampered by the lack of reliable and repeatable disease phenotypes in well structured populations. Study designs may combine dedicated experimental populations (custom bred) or commercial breeds challenged with controlled pathogens or epidemic situations. Recent successful examples include the identification ofQTL for infectious pancreatic necrosis (IPN) in full-sib commercial salmon families using microsatellites [21] and markers of tick resistance in bovine F2 populations following natural infestation [22] . In order to improve the accuracy of QTL mapping, alternative designs are being used, such as advanced intercross lines (AIL). A good example is the use of an SNP panel in chicken AIL leading to the identification of genes and possible pathways for resistance to Salmonella colonization in the chicken [23] .
APPLICATIONS IN ANIMAL HEALTH
Selection of animals with desirable health traits
What are the conditions and prerequisites to using genetic markers, as described previously, to improve disease resistance? Firstly, enough genetic variability evidenced in appropriate experiments for the disease trait of interest is required to ensure possible improvement. Secondly, as direct selection for the disease trait may be feasible in experimental conditions but not practical in commercial breeding situations, identified markers of closely linked genes having a significant effect on disease resistance phenotypes are needed. If these markers are polymorphic in the breed of interest, then marker assisted selection (MAS) strategies may be implemented. If not, alternative introgression strategies maybe considered ifproved to be worthwhile. As described previously, a shift can be observed from using microsatellite markers to SNPs. Promising examples are given from breeding companies, for instance by the Aviagen Genomics Initiative Project, which has implemented experimental SNP selection for early mortality in broilers using a two-step selection strategy [24] .
Often, QTL regions identified in the research phase are too large to be operational. Several strategies to reduce the interval, such as fine mapping or positional cloning are proving to be effective in achieving this goal. Adding enough families and applying new generation markers may turn QTL into potential tools for MAS, as. shown in fish breeding for IPN [21] . All these "from QTL to the gene" approaches are twofold: they produce reliable genetic tools to be used in selection, and identify the gene(s) and further elucidate the pathways responsible for disease resistance mechanisms (see below).
With the development ofgenome-wide SNP panels and the technological possibility of high-throughput genotyping, a new alternative to MAS has been conceived: genome wide selection (GWS) [25] . Although methodological developments are still needed to identify the best practice for using this approach in all cases, as demonstrated by Raadsma et al. for predicting merit in complex diseases such as mastitis in dairy cattle [26] , GWS may become a powerful tool of choice in the near future. GWS using high density SNP panels opens the way to unraveling the myriad of genes and underlying pathways, especially if large collaborative projects are taking place [27] .
Before implementing complex genetic strategies, the cost/benefit ratio of this approach needs to be assessed to evaluate the economic importance of the disease of interest and determine whether genetic improvement is the best alternative or merely an interesting complement to therapeutic methods. Social and ethical considerations should also be carefully investigated. From a breeder's point of view, integration of health traits into breeding programmes is very much the desired outcome of using genome-enabled technologies. However, other classical traits, such as production traits, need to be considered. The next step will be to identify the best genetic strategies to improve health and production traits in either crossbred and/or purebred animals and carry out several validation steps to confirm the success of the desired outcomes [28] .
It is foreseen that the field of breeding animals for desired traits will have to take into account a number ofparameters before it can start implementing genetic strategies that include disease resistance for infectious diseases. These parameters may have different levels of importance, depending on the animal species, the pathogen, the disease trait and its genetic control, and the environment in which the animal is raised. Since the genetics influencing host-pathogen interactions are still poorly understood, the cumulative and interactive effects ofthe environment and the evolution and ecology of the pathogen will need to be integrated into a genetic epidemiology approach to assess the long-term benefits and risks of selection [29] . An example of integration of genomics and modelization is given by a combined approach for control of the Salmonella carrier state in poultry [30] . Also, there is growing evidence that gene-by-gene interactions (epistasis) play a major role in the control of many traits including disease traits [20] . Marek's disease is one example where the interacting loci have been shown not to be located in the QTL regions associated with disease resistance [31] , showing the difficulty of using specific genes in selection. We are still in the infancy of knowing how to use in practice the complex underlying source of genetic variability and more generally to which extent data obtained in given breeds is repeatable in other breeds. This emphasizes the critical necessity for collaborative research in animal genomics, to gather a tremendous amount ofcomplex information from research organizations in the public and private sectors [27] , and the willingness to share health data sets to improve knowledge and yield subsequent tools in the near future [28] .
Using animal genomics to understand animal diseases
The sequencing of animal genomes is also providing sophisticated strategies for understanding mechanisms of disease and the biological complexities of hostpathogen interactions [32] . In particular, new approaches for understanding these interactions at the molecular level are now available through high-throughput, large scale expression analyses that are rapidly revolutionizing the analysis of whole genome responses of pathogens and their hosts [33] . In the near future, novel tools to control diseases will be available through a better understanding of disease processes, the mechanisms through which pathogens evade host immunity and the genetic basis of host-pathogen interactions.
Advanced genetic studies are now being developed towards integrating QTL data with expression data [34] . These 'genetical genomics' approaches look at genomic loci called expression quantitative loci (eQTL) from microarray studies, allied with whole genome SNP arrays (WGA) and a candidate gene approach. For example, using poultry inbred lines with defined phenotypes for susceptibility or resistance to Salmonella, Peter Kaiser et al. [35] has applied the "genetical genomics" approach to identify SNPs associated with over 400 genes linked to innate immunity. The segregation of 6,000 WGA SNPs across inbred lines yielded some 900 informative SNPs that can be used for a cross between any two lines. The function of candidate gene SNPs can now easily be tested between the inbred lines; this will contribute to our understanding of early immune responses to infection and eventually link phenotype, genotype, and eQTL.
An example ofintegrating molecular genetics and functional genomics to increase our knowledge of mechanisms of diseases is the identification of candidate genes flanking QTL previously shown to be associated with coccidiosis disease resistance
FUTURE OF ANIMAL GENOMICS IN ANIMAL HEALTH
in poultry [36] . Genome-wide searches for markers that control resistance to coccidiosis led to the identification of two major QTL associated with parasite reduction [37, 38] . Although these two QTL markers provided important information on the genetics of resistance to coccidiosis, the region in which they are located is sufficiently large to contain hundreds, if not thousands of candidate genes. A functional genomics approach to identify candidate genes flanking the QTL potentially controlling coccidiosis disease resistance consisted of using an avian intestinal intraepithelial lymphocyte cDNA array [39] constructed from a library of genes expressed by intestinal intraepithelial lymphocytes of Eimeria-infected chickens to identify candidate genes affecting gut immune responses to E. maxima infection. Another approach is combining structural and functional data by using differentially expressed genes as first candidate genes for positional cloning as an efficient strategy to map functional genes [31] orby using comparative gene ontology analyses ofdifferentially expressed genes [40] .
Global profiling of host and pathogen gene expression presents an attractive approach to identifying the novel genes involved in disease processes since genes are usually only transcribed when and where their function is required. An example is given by the refined study of the dialogue between porcine cells and pseudorabies virus at the molecular level, which has helped decipher the host response evasion strategies employed by this virus [41] . Determining the conditions under which a given gene is expressed allows inferences to be made about its function. Thus, host genomic analyses will lead to a better understanding of the response to pathogenesis, the development of diagnostic gene expression profiles, and the characterization of genetic polymorphisms associated with diseases.
Discovering a new generation of tools to control animal diseases
As discussed above, genome-enabled technologies will facilitate the selection of animals with production and health traits that target specific production systems. One of the outcomes will be the development of commercial diagnostic tests to select animals with desired traits in outbred commercial herds. Although in its infancy, animal genomics also has the potential of yielding new and improved medical therapeutics for animals that will lower production costs and improve animal welfare by fighting devastating infectious diseases that affect animals worldwide. Understanding the molecular mechanisms of disease is likely to yield logical targets for drugs and biotherapeutics, and perhaps one day transgenic animals that are resistant to infectious diseases [42] . Another important application will be the evaluation ofgenetic influences on individual animal responses to vaccination and the selection of good responders to vaccination [32, 43, 44] .
Preserving animal genetic diversity
Finally, an important consideration will be the use of genetic markers to assess and manage domestic and wildlife animal genetic diversity [29, 45] . Interestingly, the sad circumstances leading to the extinction of endangered animal species worldwide, and the loss of genetic biodiversity in domesticated livestock and poultry, could be impacted by better management of biodiversity based on new genetic markers and novel methods for genomic selection. Indeed, contrary to former genetic selection methods, which relied directly on the trait itself or using a few markers, that were accompanied with an evident risk of losing genetic variability, genomewide markers allow for the possibility of monitoring and preventing the loss of important non-selected components of animal genomes.
CONCLUSION
Genome-enabled technologies are driving fundamental changes in the approaches used to understand mechanisms of disease, the selection of animals for health traits, and the discovery of tools to control and mitigate animal diseases. Gene discovery and genetic variations can now be used in genotyping analyses. New research strategies employing high-throughput gene expression analysis are providing novel platforms for more comprehensive understanding of host-pathogen interactions. In particular, functional genomics is rapidly revolutionizing the analysis of whole genome responses of hosts and pathogens, which will ultimately lead to a better understanding of disease processes and the mechanisms through which pathogens evade host immunity; identification ofthe genetic basis ofhost-pathogen interactions; and discovery of novel vaccines, drugs, and biotherapeutics.
